1
|
King R, Sekar P, Patel H, Naveed M, Aqtash S, Adroja S, Jacob D, Riaz T. CNS toxoplasmosis, a rare presentation in a patient with Myasthenia Gravis. IDCases 2023; 32:e01780. [PMID: 37229280 PMCID: PMC10205443 DOI: 10.1016/j.idcr.2023.e01780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 04/29/2023] [Accepted: 05/02/2023] [Indexed: 05/27/2023] Open
Abstract
We report the case of a 78-year-old man with a past medical history of non-Hodgkin's lymphoma s/p chemotherapy and Myasthenia Gravis on chronic mycophenolate mofetil (MMF), who presented with altered mental status and was found to have ring enhancing brain lesions. A brain biopsy revealed organisms consistent with Toxoplasma gondii. Cerebral toxoplasmosis has been rarely reported in patients with hematologic malignancies or in those receiving immunosuppressive agents. There needs to be a high degree of suspicion for T. gondii in HIV-negative individuals who are on immunosuppressants drugs including MMF.
Collapse
Affiliation(s)
- Rachel King
- Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA
- Division of Infectious Diseases, Western Reserve Hospital, Cuyahoga falls, OH, USA
| | - Poorani Sekar
- Division of Infectious Diseases, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Henna Patel
- University-Heritage College of Osteopathic Medicine, Athens, OH, USA
| | - Maryam Naveed
- Division of Infectious Diseases, Department of Internal Medicine, Banner University Medical Center, Tucson, AZ, USA
| | - Sumaia Aqtash
- Division of Infectious Diseases, Western Reserve Hospital, Cuyahoga falls, OH, USA
| | - Shubham Adroja
- Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA
| | - Denise Jacob
- Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Talha Riaz
- Department of Internal Medicine, Cleveland Clinic Akron General, Akron, OH, USA
- Division of Infectious Diseases, Western Reserve Hospital, Cuyahoga falls, OH, USA
- Division of Infectious Diseases, Department of Internal Medicine, Banner University Medical Center, Tucson, AZ, USA
| |
Collapse
|
2
|
Durieux MF, Lopez JG, Banjari M, Passebosc-Faure K, Brenier-Pinchart MP, Paris L, Gargala G, Berthier S, Bonhomme J, Chemla C, Villena I, Flori P, Fréalle E, L’Ollivier C, Lussac-Sorton F, Montoya JG, Cateau E, Pomares C, Simon L, Quinio D, Robert-Gangneux F, Yera H, Labriffe M, Fauchais AL, Dardé ML. Toxoplasmosis in patients with an autoimmune disease and immunosuppressive agents: A multicenter study and literature review. PLoS Negl Trop Dis 2022; 16:e0010691. [PMID: 35939518 PMCID: PMC9387931 DOI: 10.1371/journal.pntd.0010691] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 08/18/2022] [Accepted: 07/21/2022] [Indexed: 11/18/2022] Open
Abstract
Background
Cases of Toxoplasma reactivation or more severe primary infection have been reported in patients receiving immunosuppressive (IS) treatment for autoimmune diseases (AID). The purpose of this study was to describe features of toxoplasmosis occurring in patients with AID treated by IS therapy, excluded HIV-positive and transplant patients.
Methods
A multicenter descriptive study was conducted using data from the French National Reference Center for Toxoplasmosis (NRCT) that received DNA extracts or strains isolated from patients, associated with clinical data. Other cases were retrieved through a questionnaire sent to all French parasitology and internal medicine departments. Furthermore, a systematic literature review was conducted.
Results
61 cases were collected: 25 retrieved by the NRCT and by a call for observations and 36 from a literature review. Half of the cases were attributed to reactivation (50.9%), and most of cases (49.2%) were cerebral toxoplasmosis. The most common associated AID were rheumatoid arthritis (28%) and most frequent treatments were antimetabolites (44.3%). Corticosteroids were involved in 60.7% of cases. Patients had a favorable outcome (50.8%) but nine did not survive. For 12 cases, a successful Toxoplasma strain characterization suggested the possible role of this parasitic factor in ocular cases.
Conclusion
Although this remains a rare condition, clinicians should be aware for the management of patients and for the choice of IS treatment.
Collapse
Affiliation(s)
- Marie-Fleur Durieux
- Department of parasitology and mycology, Dupuytren University Hospital, National Reference Center of Toxoplasmosis, Limoges Cedex, France
- * E-mail:
| | - Jean-Guillaume Lopez
- Department of internal medicine, Dupuytren University Hospital, Limoges Cedex, France
| | - Maher Banjari
- Department of internal medicine faculty of medicine -Rabigh Campus- King Abdulaziz University, Jeddah, Saudi Arabia
| | - Karine Passebosc-Faure
- Department of parasitology and mycology, Dupuytren University Hospital, National Reference Center of Toxoplasmosis, Limoges Cedex, France
| | | | - Luc Paris
- Parasitology laboratory, AP-HP Pitié-Salpêtrière, Paris, France
| | - Gilles Gargala
- Parasitology laboratory, University hospital of Rouen, Rouen, France
| | - Sabine Berthier
- Department of internal medicine, University hospital of Dijon, Dijon, France
| | - Julie Bonhomme
- Microbiology laboratory, University hospital of Caen, Caen, France
| | - Cathy Chemla
- Parasitology Laboratory, EA 7510, Reims Champagne Ardenne University, National Reference Centre on Toxoplasmosis CHU Reims, Reims, France
| | - Isabelle Villena
- Parasitology Laboratory, EA 7510, Reims Champagne Ardenne University, National Reference Centre on Toxoplasmosis CHU Reims, Reims, France
| | - Pierre Flori
- Parasitology laboratory, Hospital of Saint-Étienne, Saint-Étienne, France
| | - Emilie Fréalle
- Parasitology laboratory, University hospital of Lille, Lille, France
| | | | | | - José Gilberto Montoya
- Dr. Jack S. Remington Laboratory for Specialty Diagnostics, Palo Alto, California, United States of America
| | - Estelle Cateau
- Parasitology laboratory, University hospital of Poitiers, Poitiers, France
| | - Christelle Pomares
- Parasitology-Mycology laboratory, Côte d’Azur University, INSERM 1065, University hospital of Nice, Nice, France
| | - Loïc Simon
- Parasitology-Mycology laboratory, Côte d’Azur University, INSERM 1065, University hospital of Nice, Nice, France
| | - Dorothée Quinio
- Parasitology laboratory, University hospital of Brest, Brest, France
| | | | - Hélène Yera
- Parasitology laboratory, AP-HP Cochin, Paris, France
| | - Marc Labriffe
- Pharmacology & Transplantation, INSERM U1248, Université de Limoges, Limoges, France
| | - Anne-Laure Fauchais
- Department of internal medicine, Dupuytren University Hospital, Limoges Cedex, France
| | - Marie-Laure Dardé
- Department of parasitology and mycology, Dupuytren University Hospital, National Reference Center of Toxoplasmosis, Limoges Cedex, France
| |
Collapse
|
3
|
Wu Y, Tan Y, Ou D, Wang X, Wang Y. Azathioprine-induced toxoplasma gondii infection in a patient with Crohn's disease with NUDT15 variation: A case report. Medicine (Baltimore) 2021; 100:e25781. [PMID: 33950972 PMCID: PMC8104275 DOI: 10.1097/md.0000000000025781] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 04/15/2021] [Indexed: 01/04/2023] Open
Abstract
INTRODUCTION Azathioprine (AZA) has been widely used for the treatment of various immune-related diseases and has become a mainstay in the treatment of inflammatory bowel disease. However, patients with genetic mutations may experience severe adverse events when treated with azathioprine. Most of the previous literature focused on the TPMP gene-related adverse reactions, herein, we report a case of Crohn's disease patient with nucleoside diphosphate-linked moiety X motif 15 gene (NUDT15) variation and wild-type TPMP gene who developed toxoplasma gondii infection after azathioprine treatment. PATIENT CONCERNS A 56-year-old Crohn's disease patient developed toxoplasma gondii infection within 2 months after the administration of azathioprine; however, he had no relevant high-risk factors. DIAGNOSIS Subsequent genetic testing revealed that the patient was heterozygous for NUDT15. Therefore, it was reasonable to consider that the patient's genetic mutation resulted in reduced tolerance to azathioprine, leading to low immunity and eventually toxoplasma infection. INTERVENTIONS AZA was then discontinued; after anti-infection, antipyretic and other supportive treatments were administered, the patient's condition gradually improved. OUTCOMES The patient was followed up at 1, 3, and 6 months after discharge; fortunately, he was in good health. CONCLUSION We report a case of Crohn's disease in a patient who developed severe pneumonia caused by toxoplasma gondii infection due to the administration of AZA, with normal TPMP gene but NUDT15 gene mutation. This indicates that NUDT15 variation may contribute to severe adverse events in patients treated with azathioprine, and we suggest that NUDT15 genotype be detected before the use of azathioprine in order to provide personalized therapy and reduce side effects.
Collapse
Affiliation(s)
- Yanan Wu
- Department of Gastroenterology, The Second Xiangya Hospital
- Research Center of Digestive Disease, Central South University, Changsha, Hunan 410011, China
| | - Yuyong Tan
- Department of Gastroenterology, The Second Xiangya Hospital
- Research Center of Digestive Disease, Central South University, Changsha, Hunan 410011, China
| | - Dalian Ou
- Department of Gastroenterology, The Second Xiangya Hospital
- Research Center of Digestive Disease, Central South University, Changsha, Hunan 410011, China
| | - Xuehong Wang
- Department of Gastroenterology, The Second Xiangya Hospital
- Research Center of Digestive Disease, Central South University, Changsha, Hunan 410011, China
| | - Yongjun Wang
- Department of Gastroenterology, The Second Xiangya Hospital
- Research Center of Digestive Disease, Central South University, Changsha, Hunan 410011, China
| |
Collapse
|